145 related articles for article (PubMed ID: 10597734)
1. Novel molecular targets for prostate cancer therapy.
Kamradt JM; Pienta KJ
Semin Oncol; 1999 Apr; 26(2):234-43. PubMed ID: 10597734
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutics in colorectal cancer.
McWilliams RR; Erlichman C
Dis Colon Rectum; 2005 Aug; 48(8):1632-50. PubMed ID: 15906130
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
4. Novel therapies for advanced prostate cancer.
Konety BR; Getzenberg RH
Semin Urol Oncol; 1997 Feb; 15(1):33-42. PubMed ID: 9050138
[TBL] [Abstract][Full Text] [Related]
5. Novel targets and approaches in advanced prostate cancer.
Hadaschik BA; Sowery RD; Gleave ME
Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516
[TBL] [Abstract][Full Text] [Related]
6. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
[TBL] [Abstract][Full Text] [Related]
8. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
9. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
10. New drug development in metastatic prostate cancer.
Armstrong AJ; George DJ
Urol Oncol; 2008; 26(4):430-7. PubMed ID: 18593623
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of action of novel agents for prostate cancer chemoprevention.
Singh RP; Agarwal R
Endocr Relat Cancer; 2006 Sep; 13(3):751-78. PubMed ID: 16954429
[TBL] [Abstract][Full Text] [Related]
13. New agents in metastatic prostate cancer.
Fizazi K; Massard C
Eur J Cancer; 2009 Sep; 45 Suppl 1():379-80. PubMed ID: 19775638
[No Abstract] [Full Text] [Related]
14. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
Ryan CJ; Lin AM; Small EJ
Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
[TBL] [Abstract][Full Text] [Related]
15. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Pili R; Kruszewski MP; Hager BW; Lantz J; Carducci MA
Cancer Res; 2001 Feb; 61(4):1477-85. PubMed ID: 11245454
[TBL] [Abstract][Full Text] [Related]
16. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
[TBL] [Abstract][Full Text] [Related]
17. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
19. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody therapy for prostate cancer.
Jakobovits A
Handb Exp Pharmacol; 2008; (181):237-56. PubMed ID: 18071949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
